Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

BUY
$0.72 - $1.66 $4,794 - $11,053
6,659 Added 21.85%
37,132 $56,000
Q4 2023

Feb 14, 2024

SELL
$0.68 - $1.31 $16,347 - $31,492
-24,040 Reduced 44.1%
30,473 $26,000
Q3 2023

Nov 09, 2023

BUY
$1.14 - $1.81 $60,442 - $95,966
53,020 Added 3551.24%
54,513 $73,000
Q2 2023

Aug 09, 2023

SELL
$1.79 - $4.59 $2,894 - $7,422
-1,617 Reduced 51.99%
1,493 $2,000
Q1 2023

May 12, 2023

BUY
$2.84 - $3.92 $8,832 - $12,191
3,110 New
3,110 $12,000
Q1 2022

May 12, 2022

SELL
$5.91 - $14.38 $709,873 - $1.73 Million
-120,114 Closed
0 $0
Q4 2021

Feb 11, 2022

BUY
$5.21 - $8.61 $382,726 - $632,490
73,460 Added 157.46%
120,114 $772,000
Q3 2021

Nov 12, 2021

BUY
$4.45 - $10.63 $186,325 - $445,088
41,871 Added 875.41%
46,654 $272,000
Q2 2021

Aug 10, 2021

SELL
$8.11 - $11.11 $393,059 - $538,457
-48,466 Reduced 91.02%
4,783 $49,000
Q1 2021

May 12, 2021

SELL
$9.85 - $17.69 $307,408 - $552,087
-31,209 Reduced 36.95%
53,249 $560,000
Q4 2020

Feb 10, 2021

BUY
$14.15 - $17.19 $877,837 - $1.07 Million
62,038 Added 276.71%
84,458 $1.31 Million
Q3 2020

Nov 12, 2020

BUY
$14.14 - $19.71 $317,018 - $441,898
22,420 New
22,420 $327,000
Q4 2019

Feb 10, 2020

SELL
$9.23 - $19.67 $338,242 - $720,826
-36,646 Closed
0 $0
Q3 2019

Nov 12, 2019

BUY
$5.66 - $11.85 $158,185 - $331,183
27,948 Added 321.32%
36,646 $353,000
Q2 2019

Aug 09, 2019

SELL
$4.32 - $6.43 $91,091 - $135,582
-21,086 Reduced 70.8%
8,698 $52,000
Q1 2019

May 13, 2019

BUY
$4.12 - $10.25 $122,710 - $305,286
29,784 New
29,784 $174,000
Q2 2018

Aug 14, 2018

SELL
$12.0 - $19.88 $98,952 - $163,930
-8,246 Closed
0 $0
Q1 2018

May 11, 2018

BUY
$9.92 - $17.25 $81,800 - $142,243
8,246 New
8,246 $111,000

Others Institutions Holding KPTI

About Karyopharm Therapeutics Inc.


  • Ticker KPTI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 79,806,600
  • Market Cap $51.1M
  • Description
  • Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and in...
More about KPTI
Track This Portfolio

Track Group One Trading, L.P. Portfolio

Follow Group One Trading, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Group One Trading, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Group One Trading, L.P. with notifications on news.